Last reviewed · How we verify
WHO TBM treatment
WHO TBM treatment is a standardized therapeutic regimen combining antimicrobial agents optimized for tuberculous meningitis, targeting Mycobacterium tuberculosis in the central nervous system.
WHO TBM treatment is a standardized therapeutic regimen combining antimicrobial agents optimized for tuberculous meningitis, targeting Mycobacterium tuberculosis in the central nervous system. Used for Tuberculous meningitis (TBM).
At a glance
| Generic name | WHO TBM treatment |
|---|---|
| Also known as | Standard WHO treatment for TB meningitis |
| Sponsor | ANRS, Emerging Infectious Diseases |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
This is a clinical treatment protocol rather than a single drug entity, typically comprising isoniazid, rifampicin, pyrazinamide, and ethambutol with adjunctive corticosteroids. The regimen is designed to achieve adequate CNS penetration and bactericidal activity against TB while managing inflammation in the meninges. The Phase 3 trial likely evaluates efficacy, safety, and optimal dosing/duration for TBM management.
Approved indications
- Tuberculous meningitis (TBM)
Common side effects
- Hepatotoxicity
- Peripheral neuropathy
- Gastrointestinal disturbance
- Hypersensitivity reactions
Key clinical trials
- Real-component vs All-cement Articulating Spacers for Periprosthetic Knee Infection (NA)
- Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis (PHASE2)
- Intrathecal Therapy for Adult Tuberculous Meningitis: Impact on Clinical Outcomes
- Inhaled Tobramycin in BPD (PHASE1)
- A Study of the Clinical Benefit of Tobramycin Inhalation Solution
- Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis (PHASE3)
- Efficacy of To Be Marketed (TBM) Cholic Acid Capsules Used to Treat Children With Inborn Errors of Bile Acid Synthesis (PHASE3)
- Diagnostic Accuracy of Imaging Findings in TBM/Spinal Tubercular Arachnoiditis and Correlation With Outcomes
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- WHO TBM treatment CI brief — competitive landscape report
- WHO TBM treatment updates RSS · CI watch RSS
- ANRS, Emerging Infectious Diseases portfolio CI